RxDoctor Payments DataLook up a doctor →

Richard Orris, MD

Internal Medicine · Vernon, CTNPI 1033186598

Payments from drug & device makers

$22,336in general payments, 2019–2025

Across 1,227 payments — averaging $18.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$3K
  • AstraZeneca$2K
  • Novo Nordisk$2K
  • GSK$2K
  • Boehringer Ingelheim$1K
  • Lilly USA, LLC$1K
  • plus $11K from 54 others

What the payments were for

  • Food & beverage$22,13499%
  • Education$2021%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)160$3,010
AstraZeneca106$2,063
Novo Nordisk104$1,813
GSK106$1,695
Boehringer Ingelheim61$1,217
Lilly USA, LLC60$1,141
Pfizer57$868
Merck48$847
Sanofi-aventis U.S. LLC49$819
Amgen48$778
Astellas Pharma US Inc33$773
Novartis43$756
Johnson & Johnson43$632
Abbott34$611
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC34$516
Bayer13$427
Lundbeck LLC27$405
Phathom Pharmaceuticals, Inc.12$352
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)13$318
Amarin Pharma, Inc.15$255
Exact Sciences9$240
Scilex Pharmaceuticals Inc.13$236
Corcept Therapeutics10$236
Sumitomo Pharma America, Inc.10$233
Idorsia Pharmaceuticals US Inc13$202
E.r. Squibb & Sons, L.L.C.11$200
Sunovion Pharmaceuticals Inc.10$159
Kowa Pharmaceuticals America, Inc.10$139
Eisai Inc.4$99
Azurity Pharmaceuticals, Inc.5$91
Esperion Therapeutics, Inc.4$84
Actelion Pharmaceuticals US, Inc.3$79
Avanir Pharmaceuticals, Inc.6$77
Ardelyx, Inc.3$72
Covis Pharma GmbH4$71
Circassia Inc.5$68
Takeda Pharmaceuticals U.S.A., Inc.3$60
Biogen3$54
Otsuka America Pharmaceutical, Inc.2$54
Lifescan, Inc.3$50
Bristol Myers Squibb2$44
Shield Therapeutics Inc2$42
Dexcom, Inc.2$42
Antares Pharma, Inc.2$41
Nestle Healthcare Nutrition Inc.2$36
MDD US Operations, LLC2$35
Almatica Pharma LLC2$33
Cequr Corporation1$31
Ironwood Pharmaceuticals, Inc2$27
Arbor Pharmaceuticals, Inc.2$26
Inspire Medical Systems, Inc.1$24
Xeris Pharmaceuticals, Inc.1$23
Teva Pharmaceuticals USA, Inc.1$20
Acerus Pharmaceuticals Corporation1$19
Tactile Systems Technology Inc1$16
Currax Pharmaceuticals LLC1$15
Vifor Pharma, Inc.1$15
Amneal Pharmaceuticals LLC1$14
Daiichi Sankyo Inc.1$13
Collegium Pharmaceutical, Inc.1$12

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$22,336 in reported general payments places this provider in the 95th percentile of 2,067 internal medicine providers in Connecticut.

See all internal medicine providers in Connecticut

Medicare billing

Part B allowed, 2024
$122,173
Medicare patients
323
Services billed
1,534

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JanuviaSitagliptin Phosphate195$192,308
EliquisApixaban183$173,122
OzempicSemaglutide162$170,674
TrulicityDulaglutide63$92,698
JardianceEmpagliflozin89$90,330
MounjaroTirzepatide82$88,704
Trelegy ElliptaFluticasone/Umeclidin/Vilanter99$85,877
FarxigaDapagliflozin Propanediol54$58,961
MyrbetriqMirabegron71$58,311
XareltoRivaroxaban31$51,461
LinzessLinaclotide49$44,502
JanumetSitagliptin Phos/Metformin Hcl38$43,985
TradjentaLinagliptin36$40,949
QuliptaAtogepant12$23,942
EntrestoSacubitril/Valsartan23$17,158

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
MerckJanuvia, Janumet$847$236,293233 claims
Lilly USA, LLCTrulicity, Mounjaro$1,141$181,401145 claims
Novo NordiskOzempic, Rybelsus$1,813$181,224173 claims
PfizerEliquis$868$173,122183 claims
Boehringer IngelheimJardiance, Tradjenta$1,217$131,279125 claims
GSKTrelegy Ellipta, Anoro Ellipta, Arnuity Ellipta, Breo Ellipta$1,695$104,960146 claims
AbbVieLinzess, Qulipta, Synthroid$3,010$77,856170 claims
AstraZenecaFarxiga, Symbicort$2,063$70,39479 claims
Astellas Pharma US IncMyrbetriq$773$58,31171 claims
Johnson & JohnsonXarelto$632$51,46131 claims
NovartisEntresto$756$17,15823 claims
Sanofi-aventis U.S. LLCSoliqua 100-33$819$11,65512 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,067 internal medicine providers in Connecticut.

Other internal medicine in Vernon

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →